Citations

Clear

2285 citation(s) found for "Yu, Anthony".

Orthopaedic diagnoses in patients with Klippel-Trenaunay syndrome
Schoch, Jennifer J. , Nguyen, Henry, Anderson, Katelyn , Stans, Anthony A. , Driscoll, David, Tollefson, Megha M. , Schoch, Bradley S.

Mayo Clinic

Journal of Children's Orthopaedics | August 19, 2019 | Volume: 13 | Issue: 5 | Pages: 457-462

10.1302/1863-2548.13.190065 | PMID 31695812 Get It

Purpose Klippel-Trenaunay syndrome (KTS) is a rare combined vascular malformation composed of capillary malformation, lymphatic and/or venous malformation and limb overgrowth, which commonly affects the extremities. Due to limb involvement, it is not uncommon for these patients to require referral to an orthopaedic surgeon. Herein we reviewed the prevalence of orthopaedic diagnoses in a large cohort of KTS patients and described the associated surgical interventions. Methods Between 1976 and 2012, 410 patients fulfilling strict criteria for KTS were evaluated at a single institution. Patient charts were reviewed for demographic information, details of the clinical evaluation, orthopaedic consultation and surgical interventions. Results A total of 264 of 410 patients (64%) with confirmed KTS required orthopaedic evaluation. Of these 264 patients, 84% had documented limb-length discrepancy. Other common diagnoses included: angular deformities (10%), scoliosis (9%), osteopenia/osteoporosis (7%), pathological fractures (6%), joint contracture (5%), degenerative joint disease (4%) and limb/joint pain (4%). Of the 264 patients evaluated by orthopaedic surgery, 133 patients (50.4%) underwent 169 surgeries. Surgery was most commonly performed for limb-length discrepancy (62%). Multivariable analysis confirmed an orthopaedic condition was more likely in patients with lymphatic malformation (odds ratio (OR) 3.78; p < 0.001), as well as in those with bone and/or soft-tissue hypertrophy of the lower extremity (OR 7.51; p < 0.001) or foot (OR 3.23; p < 0.001). Conclusion Orthopaedic conditions are common in patients with KTS and approximately 50% require surgical intervention. Those with a lymphatic malformation and/or soft-tissue hypertrophy of the lower extremity are more likely to need surgery. Level of Evidence Level IV, Descriptive Case Series
Inhibition of COX‐2 Pathway as a Potential Prophylaxis Against Arthrofibrogenesis in a Rabbit Model of Joint Contracture
Salib, Christopher G. , Reina, Nicolas , Trousdale, William H. , Limberg, Afton K. , Tibbo, Megan E., Jay, Anthony G. , Robin, Joseph X. , Turner, Travis W., Jones, Carter R., Paradise, Christopher R. , Carter, Jodi M. , Berry, Daniel J., Wijnen, André J. van , Berry, Daniel J. , Lewallen, Eric A. , Sanchez-Sotelo, Joaquin, Abdel, Matthew P , van Wijnen, Andre J , van Wijnen, Andre J , Berry, Daniel J , Bolon, Brad , Berry, Daniel J., Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P. , Carter, Jodi

Mayo Clinic

Journal of Orthopaedic Research | August 14, 2019 | Volume: 37 | Issue: 12 | Pages: 2609-2620

10.1002/jor.24441 | PMID 31410880 Get It

ABSTRACTArthrofibrosis is a common complication following total knee arthroplasty caused by pathologic fibroblast activation and excessive collagen deposition around a synovial joint leading to debilitating loss of motion. Treatment options are limited because the pathologic mechanisms remain to be characterized. Dysregulation of the inflammatory cascade may lead to communication between myofibroblasts and immune cells triggering tissue metaplasia, and excessive collagen deposition described clinically as arthrofibrosis. We explored the novel use of celecoxib (selective cyclooxygenase‐2 [COX‐2] inhibitor) to disrupt the downstream effects of the post‐traumatic inflammatory cascade and inhibit scar tissue formation in a validated rabbit model of arthrofibrosis combined with new parameters for quantifying the stiffness of the posterior capsule. Biomechanical and molecular analyses, of contracted rabbit knee posterior capsule tissue after COX‐2 inhibition revealed increased maximal passive extension and down‐regulation of collagen messenger RNA compared with controls. Histopathologic examination suggested a trend of decreased quantities of dense fibrous connective tissue with COX‐2 inhibition. These data may suggest that inhibiting the inflammatory cascade could potentially reduce pathologic myofibroblast activation, thereby reducing scar tissue formation and increasing the range of motion in arthrofibrotic joints. Implementing a multi‐modal pharmacologic approach may simultaneously target numerous cellular components contributing to the complex process of arthrofibrogenesis. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:2609–2620, 2019
Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes
Din, Lennox, Kosaraju, Nikitha , Smedby, Karin E. , Berndt, Sonja I. , Skibola, Christine F., Nieters, Alexandra, Wang, Sophia , McKay, James , Cocco, Pierluigi , Foretová, Lenka , Staines, Anthony , Mack, Thomas M. , Sanjosé, Sílvia de , Vyse, Timothy J. , Padyukov, Leonid , Monnereau, Alain , Arslan, Alan A. , Moore, Amy , Brooks‐Wilson, Angela , Novak, Anne J. , Glimelius, Bengt , Birmann, Brenda M. , Link, Brian K. , Stewart, Carolyn, Vajdic, Claire M. , Magnani, Corrado , Conti, David V. , Cox, David G. , Casabonne, Delphine, Kane, Eleanor , Roman, Eve , Salles, Gilles , Adami, Hans‐Olov , Ghesquières, Hervé , Vivo, Immaculata De , Clavel, Jacqueline , Spinelli, John J., Curtin, Karen , Costenbader, Karen H. , Onel, Kenan , Offit, Kenneth , Morton, Lindsay M. , Conde, Lucía , Miligi, Lucia , Melbye, Mads , Liebow, Mark , Purdue, Mark P. , Glenn, Martha, Din, M. Azhar Ud, Rothman, Nathaniel , Camp, Nicola J. , Doo, Nicole Wong , Becker, Nikolaus, Pradhan, Nisha , Bracci, Paige M. , Vineis, Paolo , Brennan, Paul , Kraft, Peter , Lan, Qing , Severson, Richard K., Vermeulen, Roel , Kaaks, Rudolph, Travis, Ruth C. , Weinstein, Stephanie J. , Ansell, Stephen M. , Zheng, Tongzhang, Benavente, Yolanda , Taub, Zachary, Madireddy, Lohith, Gourraud, Pierre‐Antoine , Oksenberg, Jorge R. , Hjalgrim, Henrik , Khankhanian, Pouya , Cerhan, James R , Khankhanian, Pouya , Link, Brian K , Cocco, Pierluigi , Brooks-Wilson, Angela R , Vajdic, Claire M , Kane, Eleanor , Arslan, Alan A , Travis, Ruth C , De Vivo, Immaculata , Kraft, Peter , Morton, Lindsay M , Padyukov, Leonid , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Roman, Eve , Clavel, Jacqueline , Conti, David V , Doo, Nicole Wong , Sheikh, Mohammad, Bernatsky, Sasha , Maynadié, Marc , Haïoun, Corinne , Casabonne, Delphine , Albanes, Demetrius , Muzi, Giacomo , Giles, Graham G. , Cerhan, James R. , Hofmann, Jonathan N. , Vijai, Joseph , Teras, Lauren R. , Ennas, Maria Grazia , Southey, Melissa C. , Boffetta, Paolo , Milne, Roger L. , Chanock, Stephen Jacob , Slager, Susan L. , Zhang, Yawei , Cozen, Wendy

Mayo Clinic

Genetic Epidemiology | August 13, 2019 | Volume: 43 | Issue: 7 | Pages: 844-863

10.1002/gepi.22242 | PMID 31407831 Get It

AbstractEpidemiologic studies show an increased risk of non‐Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen‐stimulation in one disease leads to another. Here we assess shared genetic risk in genome‐wide‐association‐studies (GWAS).Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B‐cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of overlap, (b) polygenic risk score (PRS), (c)"diseasome", (d)meta‐analysis.Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype. The PRS of ADs were not increased in NHL patients (nor vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than solid cancers (p = .0041). A meta‐analysis (combing AD with NHL) implicated genes of apoptosis and telomere length.This GWAS‐based analysis four NHL subtypes and three ADs revealed few weakly‐associated shared loci, explaining little total risk. This suggests common genetic variation, as assessed by GWAS in these sample sizes, may not be the primary explanation for the link between these ADs and NHLs.
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
Dubey, Divyanshu , David, William S., Amato, Anthony A. , Reynolds, Kerry L. , Clement, Nathan F., Chute, Donald F., Mooradian, Meghan J. , Sullivan, Ryan J. , Guidon, Amanda C. , Cohen, Justine V, Lawrence, Donald P. , Dubey, Divyanshu , Cohen, Justine Vanessa

Mayo Clinic

Neurology | August 13, 2019 | Volume: 93 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000008091 | PMID 31405908 Get It

The international anorectal physiology working group (IAPWG) recommendations: Standardized testing protocol and the London classification for disorders of anorectal function
Carrington, Emma V. , Heinrich, Henriette , Knowles, Charles H. , Fox, Mark , Rao, Satish S.C. , Altomare, Donato F. , Bharucha, Adil E. , Burgell, Rebecca , Chey, William D. , Chiarioni, Guiseppe, Dinning, Phil G. , Emmanuel, Anton , Felt‐Bersma, R. J. F. , Malcolm, Allison , Mittal, Ravinder K., Mion, François , O’Connell, P. R. , Pehl, Christian, Reveille, R. Matthew, Vaizey, C. J. , Vitton, Véronique , Whitehead, William E. , Scott, S. Mark , Group, All members of the International Anorectal Physiology Working, Rao, Satish , Jung, Kee Wook , Lembo, Anthony , Mittal, Ravinder K , Vitton, Veronique , Whitehead, W E , Farouk, Ridzuan , Jung, Kee Wook , Lembo, Anthony , Myung, Seung‐Jae , Remes Troche, José M , Wong, Reuben K. , Group, All members of the International Anorectal Physiology Working, Malcolm, Allison

Mayo Clinic

Neurogastroenterology & Motility | August 12, 2019 | Volume: 32 | Issue: 1 | Pages: No page available

10.1111/nmo.13679 | PMID 31407463 Get It

Abstract Background This manuscript summarizes consensus reached by the International Anorectal Physiology Working Group (IAPWG) for the performance, terminology used, and interpretation of anorectal function testing including anorectal manometry (focused on high‐resolution manometry), the rectal sensory test, and the balloon expulsion test. Based on these measurements, a classification system for disorders of anorectal function is proposed. Methods Twenty‐nine working group members (clinicians/academics in the field of gastroenterology, coloproctology, and gastrointestinal physiology) were invited to six face‐to‐face and three remote meetings to derive consensus between 2014 and 2018. Key recommendations The IAPWG protocol for the performance of anorectal function testing recommends a standardized sequence of maneuvers to test rectoanal reflexes, anal tone and contractility, rectoanal coordination, and rectal sensation. Major findings not seen in healthy controls defined by the classification are as follows: rectoanal areflexia, anal hypotension and hypocontractility, rectal hyposensitivity, and hypersensitivity. Minor and inconclusive findings that can be present in health and require additional information prior to diagnosis include anal hypertension and dyssynergia. Conclusions and Inferences This framework introduces the IAPWG protocol and the London classification for disorders of anorectal function based on objective physiological measurement. The use of a common language to describe results of diagnostic tests, standard operating procedures, and a consensus classification system is designed to bring much‐needed standardization to these techniques.
Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes
Moschini, Marco , Zamboni, Stefania , Mathiéu, Romain , Xylinas, Évanguelos , Tan, Wei Shen , Kelly, John D. , Simone, Giuseppe , Meraney, Anoop, Krishna, Suprita, Konety, Badrinath R. , Mattei, Agostino , Baumeister, Philipp , Mordasini, Livio , Montorsi, Francesco , Briganti, Alberto , Sanchez‐Salas, Rafael , Cathelineau, Xavier , Rink, Michael , Karakiewicz, Pierre I. , Koupparis, Anthony , Kassouf, Wassim , Scherr, Douglas S. , Ploussard, Guillaume , Boorjian, Stephen A. , Sooriakumaran, Prasanna , Larcher, Alessandro , Simone, Giuseppe , Gallina, Andrea , Lotan, Yair , Moschini, Marco , Soria, Francesco , Baumeister, Philipp, Gallina, Andrea , Stabile, Armando , Necchi, Andrea , Rouprêt, Morgan , Lotan, Yair , Shariat, Shahrokh F.

Mayo Clinic

Journal of Clinical Medicine | August 9, 2019 | Volume: 8 | Issue: 8 | Pages: 1192

10.3390/jcm8081192 | PMID 31395826 Get It

Background: To assess the differential effect of robotic assisted radical cystectomy (RARC) versus open radical cystectomy (ORC) on survival outcomes in matched analyses performed on a large multicentric cohort. Methods: The study included 9757 patients with urothelial bladder cancer (BCa) treated in a consecutive manner at each of 25 institutions. All patients underwent radical cystectomy with bilateral pelvic lymphadenectomy. To adjust for potential selection bias, propensity score matching 2:1 was performed with two ORC patients matched to one RARC patient. The propensity-matched cohort included 1374 patients. Multivariable competing risk analyses accounting for death of other causes, tested association of surgical technique with recurrence and cancer specific mortality (CSM), before and after propensity score matching. Results: Overall, 767 (7.8%) patients underwent RARC and 8990 (92.2%) ORC. The median follow-up before and after propensity matching was 81 and 102 months, respectively. In the overall population, the 3-year recurrence rates and CSM were 37% vs. 26% and 34% vs. 24% for ORC vs. RARC (all p values > 0.1), respectively. On multivariable Cox regression analyses, RARC and ORC had similar recurrence and CSM rates before and after matching (all p values > 0.1). Conclusions: Patients treated with RARC and ORC have similar survival outcomes. This data is helpful in consulting patients until long term survival outcomes of level one evidence is available.
The Addition of an Oblique Lag Screw to T-Plate Fixation Decreases Nonunion Rate in Trapeziometacarpal Arthrodesis
Noland, Shelley S. , Cooper, Annica L., Smith, Anthony A., Pflibsen, Lacey R.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | August 8, 2019 | Volume: 7 | Issue: 7S | Pages: 4-5

10.1097/01.gox.0000579816.71820.43 Get It

Abstract LB-053: Familial studies identify variants in the E2A transcription factor as putative risk factors for lung cancer
Pikielny, Claudio W. , Mandal, Diptasri , Gaba, Colette , Li, yafang, You, Ming , Wilson, Richard K., Kupert, Elena, Anderson, Marshall W., Schwartz, Ann G. , Granizo-Mackenzie, Ambrose I., McKay, James , Hung, Rayjean, Field, John K. , Field, John K , Musolf, Anthony M. , Andrade, Mariza de , Yang, Ping , Pinney, Susan M. , Granizo-Mackenzie, Ambrose, Liu, Yanhong , Govindan, Ramaswamy , Hung, Rayjean, Christiani, David C. , Bailey‐Wilson, Joan E. , Amos, Christopher I.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: LB-053-LB-053

10.1158/1538-7445.am2019-lb-053 Get It

Abstract Lung cancer (LC) is the primary cause of cancer-related deaths in the United States. Whereas smoking and other environmental factors strongly increase LC risk, multiple genetic variants also contribute to risk in smokers. Furthermore, among smokers, some families have been identified with an abnormally high prevalence of LC, suggesting that unknown genetic factors can greatly increase LC risk in smokers. The typically short survival after LC diagnosis impedes collection of detailed genotypic information on any single large family pedigree, impairing the identification of putative high-risk factors. Therefore, the Genetic Epidemiology of LC Consortium has collected epidemiological and genetic data from a number of families with high numbers of LC cases from eight different sites across the US. In this study, we have obtained whole exome sequences (WES) from 290 members of 28 families, including 66 LC cases. We used a gene-based approach to allow for the possibility that different families may contain different variants of the same gene. Variants were filtered for i) allele frequency, ii) functional effect using combined annotation-dependent depletion (CADD), and, iii) affecting a gene with either a known or suspected role in cancer. We further selected variants based on their segregation in family pedigrees in a pattern consistent with a large effect on LC risk. Candidate LC risk genes were then identified as those represented in at least two families by the same or different variants. We further culled the list of genes by requiring the presence of at least one rare, functional variant enriched in the WES of 1060 cases relative to 899 controls from the Transdisciplinary Research on Cancer of the Lung consortium. This analysis narrowed our results to two genes, one being E2A, a member of the E family of bHLH transcription factors. Whereas loss-of-function mutations in E2A drive lymphoid cancers, the E2A protein also participates in an oncogenic heterodimer with TWIST1 that promotes the epithelial-mesenchymal transition and is implicated in multiple cancer types. Furthermore, the E2A/TWIST1 heterodimer is the primary TWIST1-containing complex implicated in oncogenesis, and silencing of E2A in KRAS-mutant non-small cell lung cancer (NSCLC) cell lines results in oncogene-stimulated senescence and apoptosis. Our data identified three distinct E2A variants present in all 10 sequenced LC cases in the 5 families in which those variants are found. Finally, two of these E2A variants are located only 57 nucleotides from each other, immediately adjacent to sequences encoding a transcription activation domain, suggesting that both variants alter the same specific protein function. These data identify E2A variants as likely high risk factors for LC in smokers and validate our general approach for identifying genetic factors with a large impact on LC risk. Citation Format: Claudio W. Pikielny, Anthony M. Musolf, Mariza de Andrade, Diptasri Mandal, Colette Gaba, Ping Yang, yafang Li, Ming You, Richard Wilson, Elena Y. Kupert, Marshall W. Anderson, Ann G. Schwartz, Susan M. Pinney, Ambrose I. Granizo-Mackenzie, Yanhong Liu, Ramaswamy Govindan, James McKay, Rayjean Hung, John K. Field, David C. Christiani, Joan E. Bailey-Wilson, Christopher I. Amos. Familial studies identify variants in the E2A transcription factor as putative risk factors for lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-053.
Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Schwab, Richard B. , Clark, Amy S. , Hylton, Nola, Wolfe, Denise, Chien, A. Jo , Forero‐Torres, Andres , Stringer-Reasor, Erica , Nanda, Rita , Jaskowiak, Nora , Haddad, Tufia C. , Han, Heather, Albain, Kathy S. , Ellis, Erin D. , Shah, Payal , Lu, Janice , Tripathy, Debasish , Kemmer, Kathleen, Haley, Barbara , Majure, Melanie, Roesch, Erin , Ewing, Cheryl, Perlmutter, Jane , Melisko, Michelle , Wilson, Amy , Singhrao, Ruby , Veer, Laura van ‘t , Asare, Smita , Berry, Don, Yau, Christina , Li, Wen , Wallace, Anne M. , Boughey, Judy C. , Lee, Catherine A. A. , Isaacs, Claudine , Elias, Anthony , Lang, Julie E. , Yee, Douglas , Vaklavas, Christos , Ewing, Cheryl A. , Helsten, Teresa L. , Symmans, W. Fraser , Rugo, Hope S. , Veer, Laura J. van’t , DeMichele, Angela , Berry, Donald A. , Esserman, Laura J.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: CT136-CT136

10.1158/1538-7445.am2019-ct136 Get It

Abstract Background: I-SPY2 is a multicenter, Phase II trial using response-adaptive randomization within biomarker subtypes to evaluate novel agents as neoadjuvant therapy for high-risk at least T2N0 breast cancer. The primary endpoint is pathologic complete response (pCR) at surgery. The goal is to identify regimens that have ≥ 85% Bayesian predictive probability of success in a 300-patient phase 3 neoadjuvant trial defined by hormone-receptor (HR) and HER2 status, and MammaPrint (MP). Regimens may leave the trial for futility (&lt; 10% probability of success), maximum sample size accrual (with probability of success ≥ 10% and &lt; 85%), or as recommended by the independent DSMB. For HER2- subjects the control arm is weekly paclitaxel x12 then doxorubicin & cyclophosphamide (AC) q2-3 weeks x4. For this arm, paclitaxel was omitted and replaced with maximum tolerated dose PARPi talazoparib with synergy dosed irinotecan (25mg/m2). Paclitaxel could be given adjuvantly for these subjects and non-responding subjects could be taken off of experimental therapy. Methods: Women with tumors ≥ 2.5cm were eligible for screening. MP low/HR+ tumors were ineligible. MRI scans (baseline, 3 cycles after start of therapy, prior to AC, and prior to surgery) were used in a longitudinal statistical model to predict pCR for individual patients. Talazoparib was given at 1mg daily with 25mg/m2 irinotecan q2wks. Analysis was intention to treat. Subjects who switched to non-protocol therapy count as non-pCR. Subjects on experimental therapy at time of arm closure are non-evaluable. Talazoparib/irinotecan (TI) was open only to HER2- tumors and eligible for graduation in 3 of 10 pre-defined signatures: HER2-, HR+HER2- and HR-/HER2-. Results: TI did not meet criteria for graduation and was stopped at the recommendation of the DSMB based on expectations of limited activity beyond that seen with standard treatment. Maximum sample size had been reached at the time of this recommendation and subjects currently receiving TI were allowed to continue or change to standard therapy. Exploratory “as treated” analysis for response in gBRCA mutation carriers showed 6/10 gBRCA carriers attained a pCR in the TI arm. Except for 1 patient these gBRCA pCR subjects had &gt;90% tumor reduction by MRI after TI and prior to AC (range: 68-96%). In the TI arm pCR rates were also higher in subjects with a PARPi7-High/MP2 gene expression signature (0.344 vs 0.146). Expected differences in toxicity were seen between arms including g3/4 peripheral neuropathy on control therapy which included paclitaxel (2.6% vs none) and g3/4 neutropenia with TI (30.2% vs 8.2%). Notably gBRCA mutation carriers receiving TI had higher rates of g3/4 neutropenia (60% vs 25.9%). Conclusion: The I-SPY2 study finds the probability that investigational regimens will be successful in a Phase III neoadjuvant trial; TI did not reach the efficacy threshold of 85% probability of success in Phase III in any of the 3 signatures. However by adding talazoparib with synergy dosed irinotecan we were able to omit paclitaxel and observe similar estimated pCR rates. This informs current work to evolve the I-SPY2 trial design to reduce toxicity without compromising outcomes and develop successful combinations targeted to biology, including DNA repair deficiency. Citation Format: Richard Schwab, Amy S. Clark, Christina Yau, Nola Hylton, Wen Li, Denise Wolfe, A Jo Chien, Anne M. Wallace, Andres Forero-Torres, Erica Stringer-Reasor, Rita Nanda, Nora Jaskowiak, Judy Boughey, Tufia Haddad, Heather S. Han, Catherine Lee, Kathy Albain, Claudine Isaacs, Anthony D. Elias, Erin D. Ellis, Payal Shah, Julie E. Lang, Janice Lu, Debasish Tripathy, Kathleen Kemmer, Douglas Yee, Barbara Haley, Melanie Majure, Erin Roesch, Christos Vaklavas, Cheryl Ewing, Teresa Helsten, W Fraser Symmans, Jane Perlmutter, Hope S. Rugo, Michelle Melisko, Amy Wilson, Ruby Singhrao, Laura van 't Veer, Angela DeMichele, Smita Asare, Don Berry, Laura J. Esserman. Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT136.